Neuroone Medical Technologies (NMTC) Cash from Financing Activities (2010 - 2026)

Neuroone Medical Technologies has disclosed Cash from Financing Activities across 16 years of filings, most recently posting $609622.0 for Q1 2026.

• Quarterly Cash from Financing Activities rose 148.61% year-over-year to $609622.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (up 135.68% YoY) and the FY2025 annual result came in at $8.0 million, up 10.45% from the prior year.
• Cash from Financing Activities rose to $609622.0 in Q1 2026, from $147823.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $8.2 million in Q2 2025 and bottomed at -$509325.0 in Q4 2024.
• The 5-year median for Cash from Financing Activities is $661961.0 (2023), against an average of $1.6 million.
• Year-over-year, Cash from Financing Activities soared 205677.95% in 2023 and tumbled 142.27% in 2024.
• Neuroone Medical Technologies' Cash from Financing Activities stood at -$15713.0 in 2022, then soared by 7768.9% to $1.2 million in 2023, then slumped by 142.27% to -$509325.0 in 2024, then jumped by 129.02% to $147823.0 in 2025, then jumped by 312.4% to $609622.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $609622.0, $147823.0, and $66978.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.